India’s first physician-designed eligibility assessment.
Built on the same criteria used in consultation.
Designed by a US-trained physician with
10+ years of GLP-1 clinical experience
across the American and Indian healthcare systems.
GLP-1 injections are now available in India from under ₹1,500 a month.
Not everyone is a candidate, and not every candidate needs the same medication.
The cheapest option is rarely the right one for the person in front of us.
This takes three minutes. You get an honest, clinically grounded answer.
No upsell.
Am I eligible for GLP-1 therapy in India? GLP-1 eligibility for Indians starts at a BMI of 27.5 with one comorbidity, or 25 with metabolic risk factors like prediabetes, PCOS, or fatty liver. Waist circumference above 90 cm in men and 80 cm in women signals visceral risk. Contraindications include thyroid cancer history, pancreatitis, and pregnancy. A physician review confirms candidacy.
The DermaVue Clinics medical team applies South Asian BMI cutoffs, waist circumference data, and comorbidity screening to determine GLP-1 eligibility, in line with the 2022 Indian Consensus on Obesity. Indian patients carry higher visceral fat at lower body weights than Western populations, so the threshold for medical therapy is 23 for overweight and 27.5 for obesity. The team operates 7 physician-led centres across Kerala and Tamil Nadu and has assessed over 7,200 patients to date. Eligibility is confirmed only after a structured contraindication check and consultation by Dr. Rejeesh M. Menon, MD Internal Medicine.
Indian BMI Eligibility Thresholds for GLP-1 Therapy
GLP-1 eligibility by BMI per Indian Society of Obesity thresholds
BMI (kg/m²)
Indian Classification
GLP-1 Eligibility
Below 23
Normal weight
Lifestyle first; physician may consider if comorbidities present
23.0 to 24.9
Overweight
Eligible with comorbidities (PCOS, prediabetes, hypertension)
25.0 to 27.4
Obese (Class I)
Eligible with comorbidity
27.5 to 29.9
Obese (Class II)
Eligible without comorbidity
30 and above
Obese (Class III)
Strong indication. Eligibility confirmed
Indian BMI thresholds per Indian Consensus Group (Misra et al., 2009, revised 2024). Western standard (overweight ≥25) underestimates cardiometabolic risk in South Asians.
INTERACTIVE ASSESSMENT
Start your free assessment below
8 clinical questions. Takes about 3 minutes. Your answers stay on your device.
GLP-1 Eligibility Assessment
LIVE
Let's start with what brings you here.
Pick the one that fits you best. We build the rest of the assessment around it.
The Method
How This Assessment Works
Tell us your profile. Weight loss, diabetes, PCOS, or prediabetes. Your answer sets the direction.
Share your numbers. Height, weight, waist. For South Asians, waist is more predictive than BMI. We use Indian thresholds, not Western ones.
Answer a short medical history. Comorbidities, contraindications, prior attempts. Eight questions total. Nothing invasive.
Get your result. A tier, a medication pathway, and a consultation path forward. Your full report delivered to WhatsApp if you want it.
Patient Profiles
Who This Assessment Is For
Profile 1. The thin-fat Indian.
Normal weight on the scale, but the waist tells a different story. Visceral fat is already metabolically active. BMI 23 with a 94 cm waist can be more dangerous than BMI 30 with a flat belly. This assessment catches that.
Profile 2. The Type 2 diabetic who wants more than sugar control.
Metformin alone, or metformin plus a sulfonylurea, is not the ceiling anymore. GLP-1 therapy gives you HbA1c reduction and weight loss in the same molecule. For most of my T2D patients, it is now the first line after metformin.
Profile 3. The PCOS patient who has tried everything.
Insulin resistance drives most PCOS-related weight gain. Diet and exercise alone rarely move the needle. Semaglutide and tirzepatide both improve insulin sensitivity, weight, and menstrual regularity. This assessment determines whether you are ready for that conversation.
2026 Context
Why Physician Supervision Matters in 2026
The semaglutide patent expired in March 2026. Forty-plus Indian manufacturers rushed to market. Prices dropped 90 percent. That is good news and a new set of risks. Quality varies across manufacturers. Counterfeit products have been intercepted. Unsupervised self-administration is rising, and so are the side effects showing up in our clinic from patients who ordered from Telegram channels.
Physician oversight matches you to the right molecule, not the cheapest one.
We monitor for Ozempic face, muscle loss, and the thyroid signal throughout treatment.
Every DermaVue GLP-1 prescription is followed up monthly with body composition tracking and side effect review.
Generic semaglutide entered the Indian market in March 2026. Branded Ozempic at 0.5 mg weekly previously ran around Rs 8,100 per month. Indian generics from Natco, Alkem, and Dr. Reddy's now sit between Rs 1,290 and Rs 4,200 at the same dose. The molecule and safety profile are identical. Physician supervision is still required because GLP-1 therapy carries real contraindications. Cheaper does not mean safer to self-prescribe.
For Indian patients I use Asian BMI cutoffs, not Western ones. A BMI of 23 to 24.9 is already overweight. A BMI of 25 or higher is obesity in the South Asian context. I consider GLP-1 therapy from a BMI of 27 if there is a comorbidity such as prediabetes, type 2 diabetes, PCOS, fatty liver, or hypertension. Without a comorbidity, the threshold is a BMI of 30. Waist circumference matters as much as BMI in our population. A waist above 90 cm in men or 80 cm in women raises the risk even when the BMI reads normal.
Almost always, yes. Current ADA and Indian diabetes guidelines now place GLP-1 receptor agonists as first line after metformin for most patients with type 2 diabetes, especially those who are overweight or have cardiovascular risk. You may have heard it called Osenpick, Ozentic, or Wigobi from a friend or a WhatsApp forward. The molecule under all those names is semaglutide. I still need to rule out a personal or family history of medullary thyroid cancer, MEN2 syndrome, active pancreatitis, and severe gastroparesis. The assessment screens for all of these.
Yes, and in my clinic PCOS is one of the most common reasons women start GLP-1 therapy. Insulin resistance is the engine of PCOS weight gain, and semaglutide and tirzepatide both improve insulin sensitivity. I have seen patients lose 8 to 12 kg over six months with their periods returning to a regular cycle in parallel. The assessment asks about PCOS specifically, because the pathway is different from a straightforward obesity case. Contraception during treatment is non-negotiable because we do not have enough human pregnancy data.
Yes. Osenpick, Ozentic, Wigobi, Wagobi, and Monjour are all phonetic spellings of Ozempic, Wegovy, and Mounjaro. Patients across Kerala and Tamil Nadu search for these medications using whatever spelling they heard from a friend or saw on WhatsApp. The molecules underneath are semaglutide (Ozempic, Wegovy, and now many Indian generics) and tirzepatide (Mounjaro, Yurpeak). Spelling does not change the pharmacology. What changes the outcome is whether a physician is titrating the dose, monitoring your body composition, and watching for side effects.
Yes. Semaglutide and tirzepatide are Schedule H prescription drugs in India. Any pharmacy or online seller offering them without a valid prescription is breaking the law. The patent expiry of semaglutide in March 2026 has made the molecule cheaper, not less regulated. I see patients every week who ordered vials from Telegram channels or grey-market sellers, and the side effects we manage from those cases are often preventable. The assessment result comes with a consultation path so the prescription is issued by a physician who has actually reviewed you.
A member of the SuperHuman team calls you within two hours of your booking. We schedule an in-person or video consultation with one of our physicians. At the consultation I review your assessment, your medical history, and we run baseline labs if they are not already done. HbA1c, fasting insulin, lipid panel, liver and kidney function, thyroid, and a body composition scan. If you are a candidate, we start you at the lowest dose and titrate monthly based on your response and tolerance. Follow-up is every four weeks for the first three months, then monthly after that.
Sometimes, yes. This is the thin-fat Indian presentation and it is under-treated in general practice. A BMI of 23 with a 94 cm waist, a fatty liver on ultrasound, and an HbA1c of 5.9 is a metabolically obese patient who happens to look slim. For these patients I consider GLP-1 therapy at a lower threshold because the visceral fat and metabolic risk are already present. The assessment asks for waist measurement specifically to catch this group. Without that number, BMI alone misses them.
Because we do not have safety data. Semaglutide and tirzepatide are excreted in animal milk and we do not know the effect on a human infant. My policy, and the position of every responsible obesity medicine specialist I know, is that we wait until you have finished breastfeeding before starting GLP-1 therapy. This is not a permanent disqualification. It is a pause. The assessment stops there because I would stop there in the consultation room.
Reviewed by
A Physician With 10+ Years in Metabolic Disease Management
This assessment and its underlying scoring rules are reviewed and signed off by
a DermaVue Clinics physician with more than a decade of experience managing
obesity, type 2 diabetes, PCOS, and metabolic disease. The output is educational,
not a prescription. A consultation is required before starting any GLP-1 therapy.